Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Tyenne (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist, antibody indicated for treatment of rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis & cytokine release syndrome.
Lead Product(s): Tocilizumab
Therapeutic Area: Immunology Product Name: Tyenne
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lead Product(s): Plerixafor
Therapeutic Area: Oncology Product Name: Mozobil-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
FYB202 (ustekinumab biosimilar) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin 23 for treatment of immune-mediated disorders.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: FYB202
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Formycon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
Idacio (adalimumab-aacf) is a biosimilar product of HUMIRA®, formulated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritisetc. The drug bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface.
Lead Product(s): Adalimumab-aacf
Therapeutic Area: Immunology Product Name: Idacio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (rituximab), through its in-house biosimilars programs and through its investment in mAbxience, Fresenius expects rapid growth in biopharmaceutical market.
Lead Product(s): Rituximab
Therapeutic Area: Oncology Product Name: Novex
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Mabxience
Deal Size: $553.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 01, 2022
Details:
Bortezomib, a new generic equivalent to Velcade® in U.S, is available in a 3.5 mg per 10mL single-dose vial presentation for subcutaneous or intravenous use, a treatment option for adult patients with multiple myeloma and mantle cell lymphoma.
Lead Product(s): Bortezomib
Therapeutic Area: Oncology Product Name: Bortezomib-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (Rituximab), through its in-house biosimilars programs and through its investment in mAbxience Fresenius expects rapid growth in biopharmaceutical market.
Lead Product(s): Rituximab,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Novex
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Mabxience
Deal Size: $553.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 31, 2022
Details:
Icatibant injection is therapeutically equivalent to Firazyr®, and supplied as a 3 mL prefilled, single-use syringe that is self-administered subcutaneously into the abdominal area.
Lead Product(s): Icatibant Acetate
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Fresenius Kabi will have the exclusive right to distribute and sell Veltassa® across China. By bringing Veltassa® to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chronic hyperkalemia.
Lead Product(s): Patiromer
Therapeutic Area: Nephrology Product Name: Veltassa
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: CSL Vifor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 19, 2020
Details:
Premier with Fresenius Kabi aims at supplying pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpatient procedures.
Lead Product(s): Heparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Premier
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 18, 2020